reports
- Maxim Jacobs
International Stem Cell - Q119 results
International Stem Cell (ISCO) reported Q119 revenues of $2.2m, down 15.8% compared with Q118 as both the biomedical and cosmetic businesses exhibited weakness. Biomedical revenues, which had been up 78.4% in 2018, were down 16.2% for the quarter. The profitability of the biomedical business also declined as revenues fell but expenses grew. The segment provided $0.8m in profits in Q118, but only $0.3m this quarter.
International Stem Cell Corporation Announces Operating Results for th...
International Stem Cell Corporation Announces Operating Results for the Quarter Ended March 31, 2019 CARLSBAD, Calif., May 17, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) () ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update announcing operating results for the three months ended March 31, 2019. "In Q1 2019 we recently achieved a major milestone in the world's first approved human pluripotent stem cell-based clinical trial for ...
International Stem Cell Corporation is Valued at $43 Million Market Va...
International Stem Cell Corporation is Valued at $43 Million Market Value by Edison Investment Research CARLSBAD, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that it has been valued at $43 million, up from $42 million in December 2018, by Edison Investment Research ("Edison")*, a world-renowned investment intelligence firm with more than one hundred analysts, investment experts,...
- Maxim Jacobs
International Stem Cell - A strong 2018 for the commercial business
International Stem Cell (ISCO) reported strong FY18 revenues of $11.1m, up 48.7% compared with 2017 mainly due to the biomedical business, which had revenues of $9.3m, up 78.4% year-on-year. The profitability of the biomedical business continues to improve as well, with operating income of $3.3m, up 78.2% compared with the previous year. The company has also reported that the 12-patient Phase I trial of ISC-hpNSC in Parkinson’s disease (PD) is now fully enrolled with complete data expected in ...
International Stem Cell Corporation Completes Enrollment and Dosing in...
International Stem Cell Corporation Completes Enrollment and Dosing in its Parkinson's Disease Clinical Trial CARLSBAD, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQX: ISCO) () ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today the completion of subject enrollment in its phase 1 clinical trial of ISC-hpNSC® for the treatment of Parkinson’s disease. The fourth subject of the third cohort, who was the twelfth and final subject of the phase 1 cl...
International Stem Cell Corporation Announces 2018 Fourth Quarter and ...
International Stem Cell Corporation Announces 2018 Fourth Quarter and Year-End Results CARLSBAD, Calif., April 15, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQX: ISCO) () ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today announced fourth quarter and year-end financial results for the period ending on December 31, 2018 and provided a business update. “During 2018 we have made significant progress towards our business units’ work optimization while also managing ...
International Stem Cell Corporation Commences Trading on the OTCQX Bes...
International Stem Cell Corporation Commences Trading on the OTCQX Best Market CARLSBAD, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQX:ISCO) () ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that it has been approved to trade on the OTCQX Best Market in the United States. International Stem Cell Corporation upgraded to the OTCQX from the OTCQB Venture Market. “I’m glad that ISCO was able to move up to the OTCQX Best Market, ...
International Stem Cell Corporation Publishes Successful Results in Tr...
International Stem Cell Corporation Publishes Successful Results in Traumatic Brain Injury CARLSBAD, Calif., Feb. 13, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) () ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that the results of the Company’s preclinical studies in traumatic brain injury (TBI) have been published in Theranostics, a prestigious peer-reviewed medical journal. The publication, titled, “Human parthenogenetic neural stem cell ...
International Stem Cell Corporation Granted Key US Patent Protecting A...
International Stem Cell Corporation Granted Key US Patent Protecting Anti-Aging Business CARLSBAD, Calif., Jan. 15, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB: ISCO) () ("ISCO" or "the Company"), a California-based, clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that the United States Patent and Trademark Office (USPTO) has granted the Company US Patent No. 10,172,890 on the topical use of lysate from human parthenogenetic (non-embryonic) stem cells to visibly improve signs of skin aging. Th...
- Maxim Jacobs
International Stem Cell - Strong biomedical sales and new clinical da...
International Stem Cell (ISCO) reported Q318 revenues of $3.2m, up 73.0% compared to Q317 mainly due to the biomedical business, which had quarterly revenues of $2.8m, up 112.8% year-on-year. Additionally, the company reported updated data from the Phase I trial of ISC-hpNSC in Parkinson’s disease (PD). At the six-month time point, the percentage OFF-Time, a key endpoint for PD treatment, decreased an average of 49% for the second cohort of patients, compared to 24% for the first, with four pa...
International Stem Cell Corporation Announces Strong Financial Results...
International Stem Cell Corporation Announces Strong Financial Results for the Three and Nine-Months ended September 30, 2018 Increases in Revenues and Profit MarginsNet Income Realized for the Quarter CARLSBAD, Calif., Nov. 15, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) () ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced operating results for the three and nine months ended September 30, 2018. "ISCO’s progres...
International Stem Cell Corporation Announces Positive Top-Line Prelim...
International Stem Cell Corporation Announces Positive Top-Line Preliminary Results from Parkinson’s Disease Clinical Trial CARLSBAD, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB: ISCO) () ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today positive 12-month results of the first cohort and six-month interim results of the second cohort of its currently-ongoing, single-arm, open-label phase 1 clinical study () evaluating the safety and tolerab...
International Stem Cell Corporation Announces Positive Top-Line Prelim...
International Stem Cell Corporation Announces Positive Top-Line Preliminary Results from Parkinson’s Disease Clinical Trial CARLSBAD, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – International Stem Cell Corporation (OTCQB: ) () ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today positive 12-month results of the first cohort and six-month interim results of the second cohort of its currently-ongoing, single-arm, open-label phase 1 clinical study () evaluating the safe...
International Stem Cell Corporation to Present Clinical Data at the So...
International Stem Cell Corporation to Present Clinical Data at the Society for Neuroscience Annual Meeting CARLSBAD, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB: ISCO) () ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today it will present at the Society for Neuroscience Annual Meeting (Neuroscience 2018), being held November 3-7, 2018 in San Diego, CA. ISCO’s presentation, titled, “Results of the first cohort of an open label dose escalati...
International Stem Cell Corporation Doses Tenth Patient in Parkinson's...
International Stem Cell Corporation Doses Tenth Patient in Parkinson's Disease Clinical Trial CARLSBAD, Calif., Oct. 08, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) () ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today that the second patient of the third cohort of the clinical trial for Parkinson's disease was successfully transplanted with 70,000,000 ISC-hpNSC® cells. The surgery, which was performed by a team of neurosurgeons at the Royal Melbou...
International Stem Cell Corporation Raised Funds Through a Private Pla...
International Stem Cell Corporation Raised Funds Through a Private Placement at Premium to Market CARLSBAD, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB: ISCO) () ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that it raised $500,000 from a private investor not affiliated with the Company or its management, at a price of $1.75 per common share, which represents a premium of over 14% compared to the closing price on September 21, 20...
- Maxim Jacobs
International Stem Cell - Biomedical sales more than double
International Stem Cell (ISCO) reported Q218 revenues of $3.0m, up 72.4% compared to Q217 mainly due to the biomedical business, which had quarterly revenues of $2.7m, up 103.1% compared to the same quarter last year. The operating profit of the biomedical business also increased substantially, up 139.6% to $1.1m. With regard to the Phase I trial of ISC-hpNSC in Parkinson’s disease (PD), the company has successfully dosed the first patient of the third cohort and expects to release interim six...
International Stem Cell Corporation Granted Key US Patent Protecting L...
International Stem Cell Corporation Granted Key US Patent Protecting Lead Therapeutic Program CARLSBAD, Calif., Aug. 21, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB: ISCO) () ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that the United States Patent and Trademark Office (USPTO) has granted the Company a key patent (US10039794) on the use of neural cells for the treatment of various neurodegenerative diseases. The patent covers the use of ISC-...
- Maxim Jacobs
International Stem Cell - Biomedical sales more than double
International Stem Cell (ISCO) reported Q218 revenues of $3.0m, up 72.4% compared to Q217 mainly due to the biomedical business, which had quarterly revenues of $2.7m, up 103.1% compared to the same quarter last year. The operating profit of the biomedical business also increased substantially, up 139.6% to $1.1m. With regard to the Phase I trial of ISC-hpNSC in Parkinson’s disease (PD), the company has successfully dosed the first patient of the third cohort and expects to release interim six...
International Stem Cell Corporation Announces Record Sales and Operati...
International Stem Cell Corporation Announces Record Sales and Operating Results for the Three and Six-Months ended June 30, 2018 CARLSBAD, Calif., Aug. 15, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) () ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced operating results for the three and six months ended June 30, 2018. “I’m pleased with our progress as ISCO continues to move forward actively in several areas. Re...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.